Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 27.2%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 289,475 shares, a growth of 27.2% from the February 26th total of 227,623 shares. Currently, 1.8% of the shares of the company are sold short. Based on an average daily trading volume, of 256,750 shares, the days-to-cover ratio is currently 1.1 days.

Allarity Therapeutics Stock Performance

Shares of ALLR opened at $1.07 on Monday. The company has a 50-day simple moving average of $1.05 and a 200-day simple moving average of $1.22. The firm has a market capitalization of $17.21 million, a P/E ratio of -1.81 and a beta of 0.20. Allarity Therapeutics has a 52 week low of $0.61 and a 52 week high of $2.35.

Hedge Funds Weigh In On Allarity Therapeutics

Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in shares of Allarity Therapeutics in the 2nd quarter worth approximately $27,000. XTX Topco Ltd acquired a new stake in shares of Allarity Therapeutics during the 4th quarter worth approximately $36,000. Geode Capital Management LLC increased its position in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after purchasing an additional 16,729 shares during the period. Citadel Advisors LLC bought a new stake in shares of Allarity Therapeutics during the third quarter valued at approximately $149,000. Finally, Capital Advisors Inc. OK acquired a new position in shares of Allarity Therapeutics in the fourth quarter valued at $108,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Analyst Upgrades and Downgrades

ALLR has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Wednesday, January 21st. Ascendiant Capital Markets raised their price objective on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.50.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.